Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBITDA (2016 - 2025)

Adma Biologics' EBITDA history spans 13 years, with the latest figure at $62.8 million for Q4 2025.

  • For Q4 2025, EBITDA rose 63.74% year-over-year to $62.8 million; the TTM value through Dec 2025 reached $191.4 million, up 37.74%, while the annual FY2025 figure was $191.4 million, 37.75% up from the prior year.
  • EBITDA reached $62.8 million in Q4 2025 per ADMA's latest filing, up from $51.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $62.8 million in Q4 2025 to a low of -$15.6 million in Q2 2021.
  • Average EBITDA over 5 years is $12.7 million, with a median of $4.1 million recorded in 2023.
  • Peak YoY movement for EBITDA: dropped 4.61% in 2021, then soared 8387.74% in 2024.
  • A 5-year view of EBITDA shows it stood at -$13.2 million in 2021, then surged by 54.07% to -$6.1 million in 2022, then skyrocketed by 334.93% to $14.2 million in 2023, then soared by 169.25% to $38.3 million in 2024, then soared by 63.74% to $62.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's EBITDA are $62.8 million (Q4 2025), $51.0 million (Q3 2025), and $42.8 million (Q2 2025).